Combigan is a medication used to treat high pressure inside the eye including glaucoma and is owned by Abbvie. It contains the active ingredient Brimonidine Tartrate; Timolol Maleate. It was first authorized for medical use in 2007. The global opthamology drug market was valued US$ 33 billion in 2022. There were 11 drug patents protecting combigan in United States, but as of now all of those 11 patents have expired.
Combigan (Brimonidine Tartrate; Timolol Maleate) currently had patent protection until January 19, 2023. This means Combigan generic become available in the market after January 19, 2023, unless a Paragraph IV certification was filed challenging the patents before expiration.
Combigan is approved to treat open-angle glaucoma and ocular hypertension in adults. The active ingredient in combigan, Brimonidine Tartrate; Timolol Maleate, is a prostaglandin analog that works by increasing the outflow of aqueous humor through the trabecular meshwork and uveoscleral routes. This lowers intraocular pressure in patients with open-angle glaucoma or ocular hypertension. combigan is administered as an ophthalmic solution/eye drops to directly target the eye for reducing elevated intraocular pressure.
Combigan currently has 11 patents covering the active ingredient, formulation, dosage, and methods of delivery that expired in April 2022 and January 2023. With patent expiration in 2023, Combigan generic can now enter the market and compete. Below is a list of the recent combigan patent expirations -